Phase 2 Trial

Ideaya Biosciences Inc (NASDAQ: IDYA) provided a clinical data update for the Phase 1/2 trial evaluating darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma (MUM) patients (eye cancer). Twenty-two (22) heavily pretreated patients enrolled in the...

Prometheus Biosciences Inc (NASDAQ: RXDX) has reported topline results from its Phase 1 trial of PRA023 in healthy volunteers. PRA023 was well-tolerated, with no safety signal identified during the study. There were no infusion reactions nor drug-related extension in infusion time,...

Bellicum will issue pre-funded warrants to purchase up to 20.6 million shares and accompanying warrants to purchase up to 2.06 million shares at a combined unit price of $1.7024. Warrants have an exercise price of $1.69 per share. Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) also ...

Ocular Therapeutix Inc (NASDAQ: OCUL) announced topline results from its Phase 2 trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease. The clinical trial achieved its pre-specified primary endpoint, demonstrating a...

GH Research PLC (NASDAQ: GHRS) has reported the outcome of the Phase 2 part of a Phase 1/2 trial of GH001, an inhalable 5-MeO-DMT product candidate for treatment-resistant depression (TRD). The trial met its primary endpoint with 7 of 8 patients (87.5%) in remission at day 7 after...

Bolt Biotherapeutics Inc (NASDAQ: BOLT) announced the presentation of interim clinical data from its Phase 1/2 study of BDC-1001. BDC-1001 is an immune-stimulating antibody conjugate (ISAC) comprising a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker...

Molecular Partners AG (NASDAQ: MOLN) announced the presentation of results from the Phase 2a study of ensovibep for COVID-19 patients and additional data from the Phase 1 study in healthy volunteers at the virtual European Scientific Working Group on Influenza (ESWI) Conference. The...

Stoke Therapeutics Inc (NASDAQ: STOK) announced highlights from five presentations related to the ongoing clinical development of STK-001 being made at the American Epilepsy Society 2021 Annual Meeting. STK-001 is under development to target the underlying cause of Dravet syndrome,...

Australia-based Kazia Therapeutics Limited (NASDAQ: KZIA) announced final data from a Phase 2 study of paxalisib as first-line therapy in patients with glioblastoma. 60mg once daily was identified as the maximum tolerated dose (MTD) and selected for future studies.  Median...

Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced additional positive data from new sub-analyses of Phase 2b X-TOLE trial of XEN1101 in adult patients with focal epilepsy. The Data will be presented at the Annual Meeting of the American Epilepsy Society. Additional primary and...

SQZ Biotechnologies Company (NYSE: SQZ) announced interim results from the highest-dose monotherapy cohort of Phase 1/2 trial of SQZ-PBMC-HPV in Human Papillomavirus positive (HPV16+) solid tumors.  The investigational cell therapy is being evaluated in certain patients with...

ARCA biopharma Inc (NASDAQ: ABIO) has completed enrollment of 160 patients in ASPEN-COVID-19 Phase 2b trial evaluating rNAPc2 for patients hospitalized with COVID-19.  The Company anticipates reporting topline data in Q1 of 2022. The trial's primary endpoint is the change...

The FDA has cleared Chemomab Therapeutics Ltd's (NASDAQ: CMMB) Investigational New Drug (IND) application for CM-101 for the rare disease primary sclerosing cholangitis (PSC). CM-101, a first-in-class CCL24-neutralizing antibody, is Chemomab's lead clinical candidate. The...

VBI Vaccines Inc (NASDAQ: VBIV) has presented updated 12-month and 18-month overall survival (OS) data from the Phase 2a study of VBI-1901, the Company's recurrent glioblastoma (GBM) vaccine VBI-1901 + granulocyte-macrophage colony-stimulating factor (GM-CSF) arm showed 18-month...

The FDA has granted Orphan Drug designation to Inhibrx Inc's (NASDAQ: INBX) INBRX-109 for chondrosarcoma. Chondrosarcoma is an orphan bone cancer with approximately 2,800 new patients diagnosed annually in the U.S. and the European Union.  Currently, there are no...